Purchase any WEBINAR and get
10% Off
CODE: SAVE10
T&C applicable, please referFAQ
Validity : 13th Apr'24 to 23rd Apr'24
Overview of FDA's Risk Evaluation and Mitigation Strategy (REMS)
- Overview of REMS Elements
- Shared Systems REMS
- The REMS Inspection Process
- Best Practices to Address Inspection Findings
- REMS Specific Issues
- Preparing for REMS Inspections
Overview of the webinar
Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. REMS are designed to reinforce medication use behaviors and actions that support the safe use of that medication.
REMS are not designed to mitigate all the adverse events of a medication, these are communicated to health care providers in the medication’s prescribing information. Rather, REMS focus on preventing, monitoring and/or managing a specific serious risk by informing, educating and/or reinforcing actions to reduce the frequency and/or severity of the event.
Who should attend?
- Operations Managers/ Supervisors
- Quality Assurance Officers
- Quality Engineering
- Validation Officers
- Engineering
Why should you attend?
Join this webinar to gain an overview of the REMS program to help applicants prepare for BIMO REMS Inspections. This session will also cover the best practices to address inspection findings.
Faculty - Ms.Kelly Thomas
Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.